Towards reliable myocardial blood-oxygen-level-dependent (BOLD) CMR using late effects of regadenoson with simultaneous 13n-ammonia pet validation in a whole-body hybrid PET/MR system
© Yang et al. 2016
Published: 27 January 2016
BOLD CMR is a non-contrast approach for examining myocardial perfusion but despite major technical advancements to date, its reliability remains weak. A key reason for this is the unpredictable cardiac motion during stress, which can lead to pronounced artifacts that confound/mask the true BOLD signal changes during hyperemia. Recently, regadenoson has become the vasodilator of choice owing to greater patient tolerability and ease of use. We hypothesized that at 10-mins post regadenoson administration (p.r.a), (a) BOLD CMR artifacts at stress are markedly reduced compared to those conventionally acquired at 2-mins p.r.a; and (b) that myocardial perfusion reserve (MPR) remains greater than 2.0 and is highly correlated with the BOLD effects estimated from T2 maps.
Canines (n = 7) were studied in a PET/MR system. MR acquisitions were used to generate short-axis 2D T2 maps; and the PET acquisitions following 13N-ammonia infusion were used to quantify myocardial blood flow (MBF). Initially, 2D T2 maps and PET signals were acquired at rest. Subsequently, regadenoson (2.5 μg/kg) was administrated. T2 maps were acquired at 2- and 10-mins p.r.a and PET signals were acquired at 10-mins p.r.a. Standard deviation (s) of myocardial T2 values was measured at rest, 2- and 10-mins p.r.a from T2 maps and were used to determine Myocardial BOLD Variability (MBV, defined as sT2(stress)/sT2(rest)) at 2- and 10-min p.r.a. Similarly, using the mean T2 values, Myocardial BOLD Response (MBR, defined as T2(stress)/T2(rest)) was computed at 10-mins p.r.a. PET images were analyzed with qPET software to determine MBF and MPR at rest and 10-mins p.r.a and were regressed against MBR
Myocardial BOLD images acquired at 10-min p.r.a (compared to 2-min p.r.a) can be free of image artifacts. MPR at 10-mins p.r.a can be consistently higher than 2.0 and is strongly correlated with MBR. These data support that delayed acquisition of BOLD CMR post regadenoson administration is a viable means for increasing the reliability of cardiac BOLD. The clinical utility of this approach remains to be evaluated in human subjects.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.